Pressmeddelanden

Breakthroughs in follow-up cancer diagnostics: Recurring cancer can be detected before it reaches full speed

Cancer treatment is becoming more and more personalised. In recent years, the greatest strides in personalised treatment have been made particularly through the development of the genetic and molecular profiling of tumors. The utilisation of information based on genetic diagnostics already offers cancer patients the opportunity to receive targeted treatment and avoid unnecessary treatment and the...

Internal radiotherapy is an effective method of treatment for metastatic prostate cancer – Docrates studied the effectiveness of 177Lu-PSMA treatment with a 4-week treatment interval

Radiopharmaceuticals such as 177Lu-PSMA target prostate cancer cells that express PSMA (prostate-specific membrane antigen), wherever they are, and make cancer treatment possible even if the cancer has spread widely. The 177Lu-PSMA radiopharmaceutical is a type of targeted radiotherapy in which the radiation source is injected directly into or in the immediate vicinity of the cancer cell. It...

A new phenomenon in the field of private cancer treatment: the number of insured patients has more than tripled in five years

Insured patients mean patients who finance their cancer diagnostics and treatment with private insurance under which the insurance compensates some of the patient’s costs. The policyholder and payer may be the patient or their employer. Commercial Director Jani Mikkola believes that the rapid growth in the number of insured patients at Docrates stems from, for example, increased knowledge about...

More and more people are seeking cancer treatment in Finland

Nearly 300 cancer patients from the Nordics underwent treatment at Docrates in 2022. Foreign patients have been treated at Docrates for more than ten years. Docrates has treated almost 2,500 foreign patients from more than 60 countries since 2019. – International patients visiting Docrates seek the latest cancer treatment methods and diagnostics that are not yet available in their home countries....